TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31177181

Group type: EXPERIMENTAL
Intervention: Habitual daily physical activity (measured by total physical activity counts - TAC)
Number of subjects: 230
Study: 28368179

Group type: EXPERIMENTAL
Intervention: TCT + SCT
Number of subjects: 111

Group type: COMPARATOR
Intervention: TCT-only
Number of subjects: 111
Study: 26299226

Group type: EXPERIMENTAL
Intervention: Risk stratification model for 30-day mortality/HF rehospitalization
Number of subjects: 7141

Group type: EXPERIMENTAL
Intervention: Risk stratification model for 30-day mortality/all-cause rehospitalization
Number of subjects: 7141

Group type: EXPERIMENTAL
Intervention: Risk stratification model for 30-day all-cause mortality
Number of subjects: 7141

Group type: EXPERIMENTAL
Intervention: Risk stratification model for 180-day all-cause mortality
Number of subjects: 7141

Group type: EXPERIMENTAL
Intervention: Simplified risk score including age, systolic blood pressure, sodium, blood urea nitrogen, and dyspnea at rest
Number of subjects: 7141
Study: 23835511

Group type: EXPERIMENTAL
Intervention: etravirine 400 mg once daily
Number of subjects: 157

Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily
Number of subjects: 157
Study: 20440633

Group type: EXPERIMENTAL
Intervention: Xenogenic graft (Gent‐Tech)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (natural healing)
Number of subjects: 22
Study: 18564231

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tolterodine-ER 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 16476160

Group type: EXPERIMENTAL
Intervention: Baseline depression assessment
Number of subjects: 681

Group type: COMPARATOR
Intervention: Follow-up survey
Number of subjects: 681
Study: 15331567

Group type: EXPERIMENTAL
Intervention: Oral trientine therapy for 7 weeks in diabetic rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral trientine treatment for 6 months in humans with type 2 diabetes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Administration of Cu-selective transition metal chelator trientine
Number of subjects: 0
Study: 10819335

Group type: EXPERIMENTAL
Intervention: Intermittent treatment (twice weekly for 6 months) with isoniazid 15 mg/kg/dose, rifampin 15 mg/kg/dose, and pyrazinamide 55 mg/kg/dose for 2 months, followed by isoniazid and rifampin only for 4 months.
Number of subjects: 206

Group type: COMPARATOR
Intervention: Daily treatment (weekday) with isoniazid 10 mg/kg/day, rifampin 10 mg/kg/day, and pyrazinamide 25 mg/kg/day for 6 months.
Number of subjects: 206
Study: 8531963

Group type: EXPERIMENTAL
Intervention: Parents and siblings of patients with adenomas
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Siblings of patients diagnosed with adenomas before 60 years of age
Number of subjects: 1031

Group type: EXPERIMENTAL
Intervention: Siblings of patients with a parent who had colorectal cancer
Number of subjects: 1031
Study: 1996926

Group type: EXPERIMENTAL
Intervention: PSL‐LBNP tests (4 tests, same protocol, separated by at least 72 h)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PSL‐LBNP tests with varying stage durations (1-, 3-, 5-, 7-, or 9-min)
Number of subjects: 20
Study: 6352280

Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) 75 mg/m2, administered i.v. bolus every 3 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Carminomycin (CMM) 20 mg/m2, administered i.v. bolus every 3 weeks
Number of subjects: 83
Study: 31146774

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at nine acupuncture points (GV20, EX-HN1, bilateral LI4, and ST36) twice a week for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham acupuncture treatment at the same points with non-penetrating sham needles
Number of subjects: 50
Study: 28748371

Group type: EXPERIMENTAL
Intervention: Heated resistance exercise (HOT30 °C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Temperate resistance exercise (CON20 °C)
Number of subjects: 16
Study: 26293925

Group type: EXPERIMENTAL
Intervention: 12 week tailored home exercise programme
Number of subjects: 70

Group type: COMPARATOR
Intervention: Advice about exercise and usual care
Number of subjects: 70
Study: 23384119

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study: 21375669

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 µg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous oxytocin 20 units
Number of subjects: 100
Study: 19075271

Group type: EXPERIMENTAL
Intervention: Oregovomab (2 mg infused over 20 minutes at weeks 0, 4, and 8, then every 12 weeks until recurrence or up to year 5)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo (infused over 20 minutes at weeks 0, 4, and 8, then every 12 weeks until recurrence or up to year 5)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Oregovomab
Number of subjects: 373

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study: 17848834

Group type: EXPERIMENTAL
Intervention: RAI+rhTSH (0.45 mg of rhTSH prior to treatment)
Number of subjects: 14

Group type: COMPARATOR
Intervention: RAI (no rhTSH pre-treatment)
Number of subjects: 14
Study: 15377348

Group type: EXPERIMENTAL
Intervention: ALA-PDT treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Light alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: ALA alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated control site
Number of subjects: 10
Study: 11855664

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day + Vitamin E 600 IU/day (G5)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Vitamin E 600 IU/day (G2)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (G4)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (G1, G3)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 140
Study: 9751554

Group type: EXPERIMENTAL
Intervention: Outside-the-boot ankle braces
Number of subjects: 777

Group type: COMPARATOR
Intervention: Non-brace wearers
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Brace wearers
Number of subjects: 777
Study: 7818590

Group type: EXPERIMENTAL
Intervention: Thymopentin treatment
Number of subjects: 0
Study: 2907315

Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30458684

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided catheter-directed thrombolysis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-guided catheter-directed thrombolysis
Number of subjects: 60
Study: 26350110

Group type: EXPERIMENTAL
Intervention: 2/100 Hz TEAS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 100 Hz TEAS
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 25432877

Group type: EXPERIMENTAL
Intervention: Daily emtricitabine/tenofovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent emtricitabine/tenofovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent placebo
Number of subjects: 0
Study: 24377213

Group type: EXPERIMENTAL
Intervention: Combined therapy of acupuncture and moxibustion
Number of subjects: 160

Group type: COMPARATOR
Intervention: Western medication (glucosamine sulfate capsules and joint cavity injections)
Number of subjects: 160
Study: 20807278

Group type: EXPERIMENTAL
Intervention: Acupuncture (ACU group, n = 17)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham acupuncture (ACU-sham group, n = 13)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n = 24)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Amiodarone (AMIO reference group, n = 26)
Number of subjects: 80
Study: 19427632

Group type: COMPARATOR
Intervention: Functional connectivity between the pACC and amygdala in BD group
Number of subjects: 33
Study: 16968802

Group type: EXPERIMENTAL
Intervention: Yohimbine (0.4 microg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 13
Study: 14557011

Group type: EXPERIMENTAL
Intervention: Cyclogest vaginal suppositories 400mg twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Crinone 8% vaginal gel once daily
Number of subjects: 60
Study: 10798738

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 78

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 78
Study: 8824669

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination with thawed frozen donor semen, prepared by double wash and swim-up
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pericervical insemination with unprepared thawed frozen donor semen
Number of subjects: 54
Study: 1730487

Group type: EXPERIMENTAL
Intervention: CVD 906 (ISP1820 delta aroC delta aroD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CVD 908 (Ty2 delta aroC delta aroD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: chi 3927 (Ty2 delta cya delta crp)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CVD 906, CVD 908, chi 3927
Number of subjects: 36
Study: 6702562

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30564971

Group type: EXPERIMENTAL
Intervention: Pharmacy-led intervention to improve medication adherence
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Morisky Scale
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Belief About Medicines Questionnaire-Specific
Number of subjects: 17
Study: 30361766

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham-IPC
Number of subjects: 8
Study: 27053383

Group type: EXPERIMENTAL
Intervention: Mineral- and vitamin-enhanced micronutrient powder (MNP)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Water-based hand sanitizer (HS)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Combination of HS and MNP
Number of subjects: 467

Group type: COMPARATOR
Intervention: Control group (no HS and no MNP)
Number of subjects: 467
Study: 25084682

Group type: EXPERIMENTAL
Intervention: Trust in primary care provider (PCP)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Trust in doctors in general
Number of subjects: 701
Study: 22182418

Group type: EXPERIMENTAL
Intervention: Ego depletion manipulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control manipulation
Number of subjects: 80
Study: 19597520

Group type: EXPERIMENTAL
Intervention: Task-specific training (up to 1 hour, three times a week for 6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no training or additional therapy)
Number of subjects: 30
Study: 18455656

Group type: EXPERIMENTAL
Intervention: Soy (50 g daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Green tea (3 g in 500 mL of water daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Soy (50 g daily) and Green tea (3 g daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (hypocholesterolemic diet)
Number of subjects: 100
Study: 16189968

Group type: EXPERIMENTAL
Intervention: Proposed integrated method for classifier fine-tuning and kinematic variable selection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bayesian classifiers with dimensionality reduction techniques
Number of subjects: 0
Study: 14509156

Group type: EXPERIMENTAL
Intervention: MUC1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Met‐HGF/SF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (malignant melanoma patients)
Number of subjects: 40
Study: 9505134

Group type: EXPERIMENTAL
Intervention: Reflex stimuli during habituation training
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Prepulse-reflex stimulus pairings during habituation training
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Random sequence of prepulse and reflex stimuli during habituation training
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Prepulse stimuli during habituation training
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Experimentally irrelevant light stimuli during habituation training
Number of subjects: 70
Study: 7785574

Group type: EXPERIMENTAL
Intervention: CT scans
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Posteroanterior and lateral radiographs (21 measurements)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Posteroanterior radiograph (2 measurements)
Number of subjects: 21
Study: 2356907

Group type: EXPERIMENTAL
Intervention: Responses of White male physicians regarding breaching confidentiality for HIV-infected patients.
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Responses of White male physicians regarding informing the patient's partner.
Number of subjects: 199
Study: 354615

Group type: EXPERIMENTAL
Intervention: Intravenous droperidol (Inapsine)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (no droperidol)
Number of subjects: 165
Study: 30573159

Group type: EXPERIMENTAL
Intervention: Annurca apple polyphenolic extract (AMS), 4 capsules/day for 24 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (maltodextrin capsules)
Number of subjects: 180
Study: 28952891

Group type: EXPERIMENTAL
Intervention: Short-term storage group (freshest available red cells, mean storage duration 11.8 days)
Number of subjects: 4994

Group type: COMPARATOR
Intervention: Long-term storage group (standard-issue red cells, mean storage duration 22.4 days)
Number of subjects: 4994

Group type: EXPERIMENTAL
Intervention: Short-term storage group
Number of subjects: 4994

Group type: COMPARATOR
Intervention: Long-term storage group
Number of subjects: 4994
Study: 26655129

Group type: COMPARATOR
Intervention: OAC-1 group (1 week treatment with omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg bid)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: OAC-2 group (2 weeks treatment with omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg bid)
Number of subjects: 298

Group type: COMPARATOR
Intervention: OAC-1 group (1 week treatment)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: OAC-2 group (2 weeks treatment)
Number of subjects: 298
Study: 23086558

Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 21996279

Group type: EXPERIMENTAL
Intervention: Quicktrach™ kit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Melker™ kit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of Quicktrach™ and Melker™ kits
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Preference indicated by residents
Number of subjects: 20
Study: 18076644

Group type: EXPERIMENTAL
Intervention: Telemedicine (n=23)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional (n=18)
Number of subjects: 41
Study: 16513521

Group type: EXPERIMENTAL
Intervention: Dosing adjusted for the source‐to‐target distance (DA group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Recommended dose prescription protocol (S group)
Number of subjects: 48
Study: 12602655

Group type: EXPERIMENTAL
Intervention: Antidepressant medication; effectiveness assessed through factor analysis; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 11493096

Group type: EXPERIMENTAL
Intervention: UV‐B 311‐nm phototherapy alone (group B)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combination of saline spa water and UV‐B therapy (group C)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Saline spa water alone (group A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 71
Study: 9612329

Group type: EXPERIMENTAL
Intervention: L‐NMMA (3 mg/kg over 10 min) during high sodium intake (250 mmol/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L‐NMMA (3 mg/kg over 10 min) during low sodium intake (77 mmol/day)
Number of subjects: 12
Study: 8296408

Group type: EXPERIMENTAL
Intervention: Erythropoietin albumin-solution
Number of subjects: 22

Group type: COMPARATOR
Intervention: Erythropoietin lyophilisate
Number of subjects: 22
Study: 3191000

Group type: EXPERIMENTAL
Intervention: Topical minoxidil
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 7984241

Group type: EXPERIMENTAL
Intervention: Bisdioxopiperazines (topoisomerase II inhibitors) such as ICRF-193
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caffeine (checkpoint-evading agent)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topoisomerase II activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catenation-sensitive checkpoint mechanism
Number of subjects: 0
Study: 32777

Group type: EXPERIMENTAL
Intervention: Tofisopam
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 30910899

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (CAZ-AVI)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Best available therapy (BAT)
Number of subjects: 284
Study: 29909113

Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography (CTA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Stress Echocardiography (SE)
Number of subjects: 400
Study: 26950350

Group type: EXPERIMENTAL
Intervention: Heavy Squat (HS) with 80% of maximum load
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unloaded Jump Squat (JS)
Number of subjects: 10
Study: 25193431

Group type: EXPERIMENTAL
Intervention: FMI (final market image)
Number of subjects: 23

Group type: COMPARATOR
Intervention: HF meal (high fat)
Number of subjects: 23

Group type: COMPARATOR
Intervention: LF meal (low fat)
Number of subjects: 23
Study: 22880108

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination of aerobic and resistance exercise
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 150
Study: 19249998

Group type: EXPERIMENTAL
Intervention: Yoga program (12-week, twice-weekly sessions including asanas and visama vritti pranayama)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Yoga program
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 29
Study: 17898245

Group type: EXPERIMENTAL
Intervention: Fluticasone 1,000 microg/day with Salmeterol 100 microg/day
Number of subjects: 137

Group type: COMPARATOR
Intervention: Fluticasone 1,000 microg/day alone
Number of subjects: 137
Study: 15078254

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (37, 16, and 10 l annually)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Control group (100 non‐donors)
Number of subjects: 583
Study: 11966951

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy for 2 years
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo treatment for 2 years
Number of subjects: 90
Study: 10325999

Group type: EXPERIMENTAL
Intervention: 2.5% topical aqueous phenylephrine
Number of subjects: 54

Group type: COMPARATOR
Intervention: 10% topical aqueous phenylephrine
Number of subjects: 54
Study: 7584198

Group type: EXPERIMENTAL
Intervention: Cryo/Cuff (CC)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ice therapy (ICE)
Number of subjects: 44
Study: 2626528

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nonspecific psychotherapy
Number of subjects: 8
Study: 776322

Group type: EXPERIMENTAL
Intervention: Drainage group
Number of subjects: 143

Group type: COMPARATOR
Intervention: Non-drainage group
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Elective drainage group
Number of subjects: 143
Study: 31509196

Group type: EXPERIMENTAL
Intervention: Fitbit ZipTM activity tracker with reporting via text messages, automated telephone calls, and syncing (two weeks each) for six weeks.
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no activity tracker).
Number of subjects: 51
Study: 31096036

Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg
Number of subjects: 3821

Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 μg
Number of subjects: 3821

Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 250/50 μg
Number of subjects: 3821
Study: 28838473

Group type: EXPERIMENTAL
Intervention: Polymer-free biolimus A9 drug-coated stents (DCS)
Number of subjects: 879

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 879
Study: 26036646

Group type: EXPERIMENTAL
Intervention: 8 weeks parent-group intervention to manage restricted and repetitive behaviours (RRB)
Number of subjects: 45
Study: 23921776

Group type: EXPERIMENTAL
Intervention: Brief Lifestyle Counseling
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Enhanced Brief LC
Number of subjects: 390

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Food records completed during the first 6 months
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Achieving a 5% weight loss at month 6
Number of subjects: 390
Study: 21464378

Group type: EXPERIMENTAL
Intervention: Couple-focused HIV prevention intervention
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control condition (basic HIV-AIDS information)
Number of subjects: 336
Study: 19458018

Group type: EXPERIMENTAL
Intervention: 300 kcal/d snack food for 2 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: 0 kcal/d snack food for 2 weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: 100 kcal/d snack food for 2 weeks
Number of subjects: 58
Study: 16885221

Group type: EXPERIMENTAL
Intervention: EBA activation during embodied self location tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TPJ activation during disembodied self location tasks
Number of subjects: 0
Study: 14738771

Group type: EXPERIMENTAL
Intervention: Masked priming paradigm with prime durations of 33 and 50 ms for upright faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masked priming paradigm with inverted faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of upright and inverted face processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misaligned faces as primes
Number of subjects: 0